Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Summer;14(3):825-32.

Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria

Affiliations

Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria

Abbas Rezaiean Mehrabadi et al. Iran J Pharm Res. 2015 Summer.

Abstract

Pioglitazone (PG) is one of thiazolidinediones used for the treatment of type II diabetes mellitus. Some reports of its hepatotoxicity exist, but the mechanism of its hepatotoxicity is not well known. In the present study, the protective effect of some ATP suppliers are investigated against mitochondrial toxicity of PG in isolated rat mitochondria. Mitochondrial viability was investigated by MTT assay. The effects of PG on superoxide dismutase activity, ATP production, mitochondrial swelling and oxidative stress were also investigated. PG reduced mitochondrial viability with an LC50 of 880±32 µM. It reduced ATP production and superoxide dismutase activity in mitochondria and increased mitochondrial swelling, but no oxidant effect was present as measured by TBARS formation. Fructose, dihydroxyacetone, dithioteritol, and N-acetylcysteine reduced mitochondrial toxicity of PG. Therefore, PG toxicity may be due to its mitochondrial toxicity and energy depletion, and ATP suppliers could be effective in preventing its toxicity.

Keywords: ATP suppliers; Mitochondria; Pioglitazone; Toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mitochondrial viability in the presence of different concentrations of pioglitazone.
Figure 2
Figure 2
Mitochondrial viability in the presence of pioglitazone and DHA (2 mM) and fructose (5 mM). ***Significantly different from control (p< 0.001).**Significantly different from pioglitazone treated (p< 0.01). *Significantly different from pioglitazone treated (p<0.05).
Figure 3
Figure 3
Mitochondrial viability in the presence of pioglitazone and DTT (0.5 mM) and NAC (0.2 mM). ***Significantly different from control (p< 0.001). **Significantly different from pioglitazone treated (p<0.01). *Significantly different from pioglitazone treated (p<0.05).
Figure 4
Figure 4
Effects of thiol reductants on mitochondrial swelling induced by pioglitazone and CaCl2.
Figure 5
Figure 5
Effect of pioglitazone and DHA (2 mM) on ATP synthesis by mitochondria. **Significantly different from control (p< 0.01). *Significantly different from pioglitazone treated (p<0.05

Similar articles

Cited by

References

    1. HE Lebovitz. Differentiating members of the thiazolidinedione class: a focus on safety, Diabetes. Metab. Res. Rev. 2002;2:23–29. - PubMed
    1. D Gerard-Monnier, S Fougeat, J Chaudiere. Glutathione and cysteine depletion in rats and mice following acute intoxication with diethylmaleate. Biochem. Pharmacol. 1992;43:451–456. - PubMed
    1. MD Aleo, CM Doshna, KA Navetta. Ciglitazone-induced lenticular opacities in rats: in-vivo and whole lens explant culture evaluation. J. Pharmacol. Exp. Ther. 2005;312:1027–1033. - PubMed
    1. SE Nissen, K Wolski, EJ Topol. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA Nov. 2005;294:2581–2586. - PubMed
    1. RB Marcy Todd, M Steve. Second-generation thiazolidindiones and hepatotoxicity. Ann. Pharmaco. Ther. 2004;38:1419–1423. - PubMed

LinkOut - more resources